Notably, among activator E2Fs, E2F3 appeared to induce ACSL4 expression to the greatest degree in RB-knockdown PC3 cells (Figure 2D) and displayed a stronger correlation with ACSL4 in human prostate cancer samples than E2F1 (Figure 2, O and P, and Supplemental Figure 4, C and D), suggesting that E2F3 may be the primary E2F member driven by RB1 loss to regulate ACSL4 expression in prostate cancer. The gene discussed is ACSL4; the disease is prostate carcinoma.